Xtant Medical Holdings, Inc. (XTNT) - Dilution Analysis

10-Q filing | 139.7M shares outstanding

POS AM filing: This post-effective amendment deregisters and removes from registration several previously filed registration statements related to the resale of common stock and convertible notes.

S-1 filing: This S-1 filing relates to the resale of up to 73,114,592 shares of common stock of Xtant Medical Holdings, Inc. by selling stockholders.

POS AM filing: These Post-Effective Amendments relate to Registration Statements previously filed by Xtant Medical Holdings, Inc. and are being filed to deregister and remove from registration certain shares of common stock and other securities; the offerings of the securities described above pursuant to the Registration Statements have terminated.

POS AM filing: Post-Effective Amendments being filed to deregister and remove from registration several registration statements previously filed by Xtant Medical Holdings, Inc., as the offerings of the securities described have terminated.

10-Q filing | 139.1M shares outstanding

POS AM filing: Post-Effective Amendments relate to Registration Statements previously filed by Xtant Medical Holdings, Inc. to deregister and remove from registration.

POS AM filing: These Post-Effective Amendments relate to Registration Statements previously filed by Xtant Medical Holdings, Inc. and are being filed to deregister and remove from registration the shares of common stock and other securities.

POS AM filing: Post-Effective Amendments being filed to deregister and remove from registration several Registration Statements previously filed by Xtant Medical Holdings, Inc., as the offerings of the securities described pursuant to the Registration Statements have terminated.

POS AM filing: This is a post-effective amendment to deregister and remove from registration several registration statements related to the resale of common stock and other securities.

POS AM filing: These Post-Effective Amendments relate to Registration Statements previously filed by Xtant Medical Holdings, Inc. and are being filed to deregister and remove from registration the listed offerings because the offerings of the securities described above pursuant to the Registration Statements have terminated.

POS AM filing: Post-Effective Amendments relate to previously filed Registration Statements by Xtant Medical Holdings, Inc. to deregister and remove from registration shares of Common Stock and other securities, as the offerings of these securities have terminated.

8-K filing: A privately negotiated transaction involved the sale of approximately 73.1 million shares of common stock, representing 52.5% of the company's outstanding common stock, from the Sellers to the Purchasers as of April 15, 2025; Nantahala owns approximately 49.1% of the Company's outstanding Common Stock as of April 15, 2025.

10-K filing | 133.7M shares outstanding

10-Q filing | 135.1M shares outstanding

POS AM filing: This prospectus relates to our common stock, preferred stock, warrants to purchase our common stock or preferred stock, and units comprised of any combination of these securities that we may sell from time to time in one or more offerings up to a total public offering price of $150,000,000 on terms to be determined at the time of sale.

S-3 filing: This prospectus relates to the resale of up to 7,812,500 shares of common stock by selling stockholders who acquired these shares from the company pursuant to a Securities Purchase Agreement dated August 7, 2024.

10-Q filing | 130.3M shares outstanding

8-K filing: Xtant Medical Holdings, Inc. entered into a securities purchase agreement to issue 7,812,500 shares of common stock at $0.64 per share in a private placement, with gross proceeds expected to be $5.0 million. ($5.0M proceeds)

10-Q filing | 130.2M shares outstanding

S-3 filing: This S-3 filing is for the potential sale of common stock, preferred stock, warrants to purchase common stock or preferred stock, and units comprised of any combination of these securities up to a total public offering price of $150,000,000, as well as the resale of up to 18,218,374 shares of common stock by selling stockholders.

10-K filing | 126.8M shares outstanding

10-Q filing | 128.1M shares outstanding

10-Q filing | 128.9M shares outstanding

S-3/A filing: S-3/A filing for Registration Rights Agreement (for Common Stock issued upon the exchange of the Notes and pursuant to the Private Placement) dated as of February 14, 2018.

S-3 filing: This S-3 filing relates to the resale of up to 20,000,000 shares of common stock by selling stockholders, who acquired these shares in a private placement on July 3, 2023, at a per share price of $0.75.

8-K filing: Xtant Medical Holdings, Inc. entered into a securities purchase agreement to issue 20,000,000 shares of common stock in a private placement at a price of $0.75 per share, with gross proceeds expected to be $15.0 million. ($15.0M proceeds)

10-Q filing | 108.9M shares outstanding

10-K filing | 108.9M shares outstanding

10-Q filing | 108.7M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 25,381,787 shares of common stock of Xtant Medical Holdings, Inc. by the selling stockholders.

8-K filing: Xtant Medical Holdings, Inc. closed the second and final tranche of its previously announced $9.75 million private placement, selling an additional approximately 6.2 million shares of common stock and warrants to purchase approximately 1.6 million shares of common stock for an aggregate purchase price of approximately $3.0 million. ($3.0M proceeds)

8-K filing: Xtant Medical Holdings, Inc. closed the first tranche of its previously announced private placement on August 25, 2022, selling approximately 14.1 million shares of common stock and warrants to purchase approximately 3.5 million shares for an aggregate purchase price of approximately $6.75 million. ($0.0M proceeds)

8-K filing: Xtant Medical Holdings, Inc. entered into a securities purchase agreement to issue 20,305,429 shares of common stock and warrants to purchase up to 5,076,358 shares in a private placement, with gross proceeds expected to be approximately $9.75 million. ($9.75M proceeds)

10-Q filing | 87.3M shares outstanding

10-Q filing | 87.2M shares outstanding

10-K filing | 85.5M shares outstanding

10-Q filing | 86.8M shares outstanding

10-Q filing | 86.7M shares outstanding

10-Q filing | 77.6M shares outstanding

S-3 filing: This prospectus relates to our common stock, preferred stock, warrants to purchase our common stock or preferred stock, and units comprised of any combination of these securities that we may sell from time to time in one or more offerings up to a total public offering price of $150,000,000 on terms to be determined at the time of sale.

S-3 filing: This S-3 filing registers the resale of shares of common stock by selling stockholders.

10-K filing | 77.6M shares outstanding

POS AM filing: The company is filing a post-effective amendment to deregister 13,306,044 shares of common stock that remained unsold in the Rights Offering.

8-K filing: Xtant Medical Holdings, Inc. entered into a securities purchase agreement for a private placement of 8,888,890 shares of common stock at $2.25 per share and warrants to purchase up to 6,666,668 shares, expecting gross proceeds of approximately $20 million. ($20.0M proceeds)

S-1 filing: This prospectus relates to the resale of up to 58,754,394 shares of common stock of Xtant Medical Holdings, Inc. by the selling stockholders.

8-K filing: ROS Acquisition Offshore LP and OrbiMed Royalty Opportunities II, LP exercised warrants representing 4.8 million shares of Xtant Medical Holdings, Inc. common stock for aggregate proceeds of $48,000. ($0.05M proceeds)

S-1/A filing: The company is conducting a rights offering to allow stockholders to purchase common stock at $1.07 per share.

10-Q filing | 13.2M shares outstanding

8-K filing: Xtant Medical Holdings, Inc. issued approximately 57.8 million shares of common stock at $1.07 per share in exchange for approximately $40.8 million of debt and $21.1 million of PIK Interest.

8-K filing: Xtant Medical Holdings, Inc. issued 57,837,045 shares of Common Stock to lenders in exchange for approximately $40.8 million of debt and $21.1 million of PIK interest at an exchange price of $1.07 per share and issued additional shares for a prepayment fee.

S-1 filing: The company is conducting a rights offering to allow stockholders to purchase common stock at the same price per share that was offered to lenders in exchange for the extinguishment of certain loans.

8-K filing: Xtant Medical Holdings, Inc. entered into a Restructuring and Exchange Agreement with OrbiMed Royalty Opportunities II, LP and ROS Acquisition Offshore LP to restructure outstanding indebtedness, including exchanging approximately 57.8 million shares of Common Stock for approximately $40.8 million of loans and $21.1 million of PIK Interest at $1.07 per share. ($61.85M proceeds)

10-Q filing | 13.2M shares outstanding

10-Q filing | 13.2M shares outstanding

10-K filing | 13.2M shares outstanding